Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label active-controlled study of HSA-rhGH in children with growth hormone deficiency
CTR20241643Phase 3Active
- Sponsor
- Zhejiang Unicon Bioengineering
- Start
- Jun 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of albusomatropin in growth hormone deficiency (GHD), sponsored by Zhejiang Unicon Bioengineering. Started Jun 2024; status: active.
02
Drugs
albusomatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on CTR20241643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241643.